

Exciting New Challenges Ahead for Dr. Linda Rhodes

January 7, 2011 – We are pleased to announce that Linda Rhodes has accepted a new challenge, and is leaving AlcheraBio as of February 2011 to become the CEO of Aratana Therapeutics, a specialty animal health biopharmaceutical company based in Kansas City, Kansas. Aratana’s mission is to employ a virtual development strategy to bring new animal health drugs to the animal health industry, sourced from human health new chemical entities.

Ten years ago, in April 2001, Linda Rhodes and Katherine Moldave founded AlcheraBio. Our entrepreneurial culture has been at the core of our business, and over the years AlcheraBio has evolved into a full-service, fully staffed veterinary clinical Contract Research Organization. In October 2008 the company was acquired by Argenta, an international animal health formulations R&D and manufacturing company headquartered in New Zealand. Now our clients have turnkey access to drug development services from formulations development and clinical development through manufacturing and postmarketing support.

“Building AlcheraBio over the last decade has been very fulfilling,” Linda says, “and we have a terrific staff that is well respected by our clients. I have transitioned my projects to other AlcheraBio staff and AlcheraBio is strong, thriving, and well positioned to take on additional work. In addition, Aratana Therapeutics has agreed to allow me to continue to be available to AlcheraBio clients for questions or necessary follow up work in 2011 to assure a smooth transition. I have every faith that AlcheraBio will continue to provide exceptional services to the animal health industry.”

AlcheraBio COO Dr. Johnny Jacobsen notes “We are delighted for Linda and supportive of her as she transitions to her new position. She is an excellent fit with Aratana’s mission and culture. She has been a mentor to members of AlcheraBio’s clinical staff as they have evolved to assume increasing responsibility over the years. As AlcheraBio announced in December 2010, Dr. Jane Eagleson has relocated from Argenta, AlcheraBio’s parent company, to AlcheraBio headquarters in New Jersey. Jane is experienced in clinical development and has already assumed responsibility for a number of AlcheraBio’s clinical research projects. We will also be making additional personnel-related announcements about our plans to grow AlcheraBio’s capacity for clinical research in the near future.”